Brian A. Whiteman

Array ( [id] => 17037108 [patent_doc_number] => 20210254066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => Nucleic Acid Molecules and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/247265 [patent_app_country] => US [patent_app_date] => 2020-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11401 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17247265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20593864 [patent_doc_number] => 12577568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Methods for controlling extracorporeal membrane oxygenation (ECMO) coagulation [patent_app_type] => utility [patent_app_number] => 17/782848 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 34 [patent_no_of_words] => 5851 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511645 [patent_doc_number] => 20230227820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => RNA INTERFERENCE-INDUCING NUCLEIC ACID COMPRISING 8-OXOGUANINE, MODIFIED NUCLEIC ACID BINDING TO MICRORNA COMPRISING 8-OXOGUANINE, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/780600 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091311 [patent_doc_number] => 20220409652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => miRNA-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND THE TREATMENT OF TISSUE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/781150 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20771768 [patent_doc_number] => 12655429 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-16 [patent_title] => MicroRNA as a therapeutic agent [patent_app_type] => utility [patent_app_number] => 17/779293 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 66 [patent_no_of_words] => 45473 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883723 [patent_doc_number] => 20210169918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 16/949980 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839830 [patent_doc_number] => 20210147842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING NECROPTOSIS IN NEUROVASCULAR AND/OR NEURODEGENERATIVE DISEASES OR DISORDERS [patent_app_type] => utility [patent_app_number] => 17/097695 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976037 [patent_doc_number] => 20210220274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY [patent_app_type] => utility [patent_app_number] => 17/094724 [patent_app_country] => US [patent_app_date] => 2020-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109886 [patent_doc_number] => 20230002766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/775148 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005309 [patent_doc_number] => 20220364075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => METHODS OF MODIFYING A NUCLEIC ACID SEQUENCE [patent_app_type] => utility [patent_app_number] => 17/774411 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16808275 [patent_doc_number] => 20210130828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => GIN RECOMBINASE VARIANTS [patent_app_type] => utility [patent_app_number] => 17/085319 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793240 [patent_doc_number] => 20210123057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => Sequence Multiplicity Within Spherical Nucleic Acids [patent_app_type] => utility [patent_app_number] => 17/084460 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156167 [patent_doc_number] => 20240148874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => IMMUNOADJUVANT-BASED HYDROGEL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/044565 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18181764 [patent_doc_number] => 20230042493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => CTGF GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE, AND A COMPOSITION FOR PREVENTING AND TREATING FIBROTIC DISEASES AND RESPIRATORY-RELATED DISEASES COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/778836 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14945 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762631 [patent_doc_number] => 20210108212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/080771 [patent_app_country] => US [patent_app_date] => 2020-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612198 [patent_doc_number] => 20210030851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 17/072056 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7678 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067597 [patent_doc_number] => 20240102023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => NOVEL RNA APTAMER INTERVENES ESTROGEN RECEPTOR INTERACTION WITH COACTIVATOR MED1 TO OVERCOME BREAST CANCER METASTASIS [patent_app_type] => utility [patent_app_number] => 17/768023 [patent_app_country] => US [patent_app_date] => 2020-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762620 [patent_doc_number] => 20210108201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => FN3 Domain-siRNA Conjugates and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/070337 [patent_app_country] => US [patent_app_date] => 2020-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17070337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16728163 [patent_doc_number] => 20210095310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => MICRORNA REGULATED EXPRESSION VECTORS, METHODS OF MAKING, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/067572 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12873 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598403 [patent_doc_number] => 20210024934 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/063610 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063610 [rel_patent_id] =>[rel_patent_doc_number] =>)